These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 14644513)
1. Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models. Cook JW; Sterman DH; Singhal S; Smythe WR; Kaiser LR Lung Cancer; 2003 Dec; 42(3):263-74. PubMed ID: 14644513 [TBL] [Abstract][Full Text] [Related]
2. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Suzuki E; Kim S; Cheung HK; Corbley MJ; Zhang X; Sun L; Shan F; Singh J; Lee WC; Albelda SM; Ling LE Cancer Res; 2007 Mar; 67(5):2351-9. PubMed ID: 17332368 [TBL] [Abstract][Full Text] [Related]
3. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. Chahinian AP; Mandeli JP; Gluck H; Naim H; Teirstein AS; Holland JF J Surg Oncol; 1998 Feb; 67(2):104-11. PubMed ID: 9486781 [TBL] [Abstract][Full Text] [Related]
6. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Miselis NR; Wu ZJ; Van Rooijen N; Kane AB Mol Cancer Ther; 2008 Apr; 7(4):788-99. PubMed ID: 18375821 [TBL] [Abstract][Full Text] [Related]
7. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826 [TBL] [Abstract][Full Text] [Related]
8. The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis. Colson YL; Liu R; Southard EB; Schulz MD; Wade JE; Griset AP; Zubris KA; Padera RF; Grinstaff MW Biomaterials; 2011 Jan; 32(3):832-40. PubMed ID: 21044799 [TBL] [Abstract][Full Text] [Related]
9. Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model. Davol PA; Garza S; Frackelton AR Cancer; 1999 Nov; 86(9):1733-41. PubMed ID: 10547546 [TBL] [Abstract][Full Text] [Related]
10. Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. Mezzapelle R; Rrapaj E; Gatti E; Ceriotti C; Marchis FD; Preti A; Spinelli AE; Perani L; Venturini M; Valtorta S; Moresco RM; Pecciarini L; Doglioni C; Frenquelli M; Crippa L; Recordati C; Scanziani E; de Vries H; Berns A; Frapolli R; Boldorini R; D'Incalci M; Bianchi ME; Crippa MP Sci Rep; 2016 Mar; 6():22850. PubMed ID: 26961782 [TBL] [Abstract][Full Text] [Related]
11. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Odaka M; Sterman DH; Wiewrodt R; Zhang Y; Kiefer M; Amin KM; Gao GP; Wilson JM; Barsoum J; Kaiser LR; Albelda SM Cancer Res; 2001 Aug; 61(16):6201-12. PubMed ID: 11507073 [TBL] [Abstract][Full Text] [Related]
12. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. Kruklitis RJ; Singhal S; Delong P; Kapoor V; Sterman DH; Kaiser LR; Albelda SM J Thorac Cardiovasc Surg; 2004 Jan; 127(1):123-30. PubMed ID: 14752422 [TBL] [Abstract][Full Text] [Related]
13. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Nici L; Monfils B; Calabresi P Clin Cancer Res; 2004 Nov; 10(22):7655-61. PubMed ID: 15569998 [TBL] [Abstract][Full Text] [Related]
14. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. Zhang Y; Song S; Yang F; Au JL; Wientjes MG J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651 [TBL] [Abstract][Full Text] [Related]
15. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896 [TBL] [Abstract][Full Text] [Related]
16. Effect of suramin on human esophageal cancer cells in vitro and in vivo. Shin R; Naomoto Y; Kamikawa Y; Tanaka N; Orita K Scand J Gastroenterol; 1997 Aug; 32(8):824-8. PubMed ID: 9282976 [TBL] [Abstract][Full Text] [Related]
17. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045 [TBL] [Abstract][Full Text] [Related]
18. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Lanuti M; Rudginsky S; Force SD; Lambright ES; Siders WM; Chang MY; Amin KM; Kaiser LR; Scheule RK; Albelda SM Cancer Res; 2000 Jun; 60(11):2955-63. PubMed ID: 10850443 [TBL] [Abstract][Full Text] [Related]
19. Suramin selectively inhibits carcinoma cell growth that is dependent on extracellular polyamines. Sandgren S; Belting M Anticancer Res; 2003; 23(2B):1223-8. PubMed ID: 12820375 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice. Church D; Zhang Y; Rago R; Wilding G Cancer Chemother Pharmacol; 1999; 43(3):198-204. PubMed ID: 9923549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]